COVID-19 Pandemic
Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story). In preclinical studies, the molecule was effective at a very low antibody concentration. The company discovered STI-1499 by screening its proprietary G-MAB™ fully human antibody library. Sorrento will include STI-1499 in a three-molecule "protective shield" against SARS-CoV-2 being developed with Mt. Sinai Hospital and as a stand-alone product.
Deals and Financings
Nanjing Legend Biotech will stage a $100 million US IPO